March 9, 2026
* The patients treated with the drug, tilrekimig, saw asignificant reduction in symptoms after 16 weeks and the drugwas well tolerated with a favorable safety profile […]
March 5, 2026
TOPLINE: Physical activity was associated with a reduced risk for all-cause mortality among patients with cutaneous melanoma (CM) or non-melanoma skin cancers (NMSCs), according to a […]
March 4, 2026
TOPLINE: A study of 1092 patients with stage IA to IIC melanomas identified several factors associated with recurrence, including tumor location on the scalp or neck, […]
March 4, 2026
Medication authorization letters, patient handouts, and patient triage are among top use cases of AI in DermGPT and are likely the top applications in dermatology across […]
March 3, 2026
TOPLINE: Patients with new-onset alopecia areata (AA) had a significantly higher 10-year risk of developing multiple immune-mediated inflammatory diseases (IMIDs), a study reports. METHODOLOGY: Researchers used […]
February 27, 2026
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization to Rhapsido (remibrutinib, Novartis), an oral pill for treating […]
February 26, 2026
TOPLINE: Bimekizumab showed sustained improvements in International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS) over 48 weeks, with a […]
February 26, 2026
TOPLINE: Implementation of an emergency department (ED)-initiated walk-in dermatology pathway significantly reduced wait times for patients with atopic dermatitis (AD) and hidradenitis suppurativa (HS), and the […]
February 25, 2026
TOPLINE: In a cross-sectional analysis of approximately 11,000 clinical visits at Mexico-US border camps from 2020 to 2022, dermatologic conditions accounted for 6% of encounters and […]